20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.

ABSTRACT:

Background

The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such therapy beyond 5 years offers further protection but has additional side effects. Obtaining data on the absolute risk of subsequent distant recurrence if therapy stops at 5 years could help determine whether to extend treatment.

Methods

In this meta-analysis of the results of 88 trials involving 62,923 women with ER-positive breast cancer who were disease-free after 5 years of scheduled endocrine therapy, we used Kaplan-Meier and Cox regression analyses, stratified according to trial and treatment, to assess the associations of tumor diameter and nodal status (

SUBMITTER: Pan H 

PROVIDER: S-EPMC5734609 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature